PAR Technology Corp (PAR.N)
PAR.N on New York Stock Exchange
3.99USD
24 May 2013
3.99USD
24 May 2013
Price Change (% chg)
$0.02 (+0.50%)
$0.02 (+0.50%)
Prev Close
$3.97
$3.97
Open
$3.90
$3.90
Day's High
$4.00
$4.00
Day's Low
$3.90
$3.90
Volume
1,600
1,600
Avg. Vol
4,002
4,002
52-wk High
$5.55
$5.55
52-wk Low
$3.80
$3.80
About
PAR Technology Corporation (PAR) conducts business in two business segments: Hospitality and Government. The Hospitality segment offers hardware, software technology solutions and a range of support services, to businesses and organizations in the global hospitality industries. These offerings include hardware and software... (more)
No analyst recommendations are available for PAR.N.
Overall
| Beta: | 1.30 |
| Market Cap (Mil.): | $61.37 |
| Shares Outstanding (Mil.): | 15.38 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| PAR.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 16.56 | 24.40 | 28.75 |
| EPS (TTM): | 0.24 | -- | -- |
| ROI: | 4.68 | 22.45 | 14.82 |
| ROE: | 4.95 | 24.08 | 16.09 |
UPDATE 1-Argentina makes bond coupon payments amid legal row
LONDON/BUENOS AIRES, April 3 - Argentina has made a scheduled coupon payment on its 2038 Par bonds and will pay interest on its 2015 Boden bonds later on Wednesday, a spokeswoman at the country's Economy Ministry said.
UPDATE 2-Argentina to offer holdouts mix of Par, Discount bonds-report
* Newspaper says offer to include some $450 mln in Par bonds
UPDATE 3-U.S. drugmaker admits misbranding AIDS appetite medicine
March 5 - Par Pharmaceutical Cos, a generic drugmaker, has pleaded guilty to improperly marketing a medication intended to address appetite loss in AIDS patients, and agreed to pay $45 million to resolve a federal criminal probe and related civil litigation.
Competitors
| Price | Change | |
|---|---|---|
| Panasonic Corporation (6752.T) | ¥894 | +8.00 |
| International Business Machines Corp. (IBM.N) | $205.72 | -0.44 |
| NCR Corporation (NCR.N) | $31.66 | +0.12 |
| MICROS Systems, Inc. (MCRS.OQ) | $42.71 | -0.30 |

Earnings vs.
Estimates